Preparation method of monapiravir and intermediate of monapiravir

CN118922430APending Publication Date: 2024-11-08SHANGHAI SYNCORES TECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380022626.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-03
Filing Date
2023-03-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing preparation method of monabilavir has problems in industrial production such as high starting material prices, low overall yield, use of highly toxic phosphorus oxychloride and the generation of a large amount of acidic wastewater, and the enzyme catalyzed reaction requires conditions. High, the intermediate is unstable, the monoacylation efficiency is low, and the product is difficult to separate and purify.

Method used

The compound of formula III is reacted with acetone under acidic conditions, then reacted with isobutyryl chloride or isobutyric anhydride under alkaline conditions, then reacted with ammonia or hydroxylamine, and finally the protecting group is removed under the action of acid to obtain monabilat Wei, a step process with high directional conversion rate and few side reactions through the diacylation of intermediates IV and V.

Benefits of technology

Provides a method for preparing monabiravir with cheap raw material sources, no enzyme catalyzed reaction, mild reaction conditions, simple operation, stable quality and high overall yield, which is suitable for industrial production, reduces the amount of three wastes, and simplifies the production of the product Separation and purification process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922430A_ABST
    Figure CN118922430A_ABST
Patent Text Reader

Abstract

The preparation method comprises the following steps: taking a compound (IV) as a raw material, reacting the compound (IV) with isobutyryl chloride or isobutyric anhydride under an alkaline condition to obtain an intermediate compound (V), and reacting the intermediate compound (V) with ammonia water or hydroxylamine to obtain a compound shown in a formula (VI); and then removing a protecting group under the action of acid to obtain monadavir as shown in the formula (I). The method has the advantages of high yield, few side reactions and the like. Synthetic route as follows: # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

A preparation method of monabivir and its intermediates Technical Field

[0001] The present invention relates to a preparation method of monabivir and an intermediate thereof, and belongs to the field of pharmaceutical chemical industry. Background Art

[0002] Molnupiravir, also known as EIDD-2801, has a structural formula as shown in Formula I:

[0003] It is a ribonucleoside analogue N 4 -The isopropyl ester prodrug of hydroxycytidine (also known as NHC, EIDD-1931) can inhibit the replication of various RNA viruses and is the world's first oral drug for the treatment of the new coronavirus COVID-19.

[0004] The main preparation methods reported so far are:

[0005] Route 1: Patent WO2019113462 reports the use of uridine as a raw material. The dihydroxyl group is protected with acetone formate, then reacted with isobutyric anhydride for esterification. This is followed by condensation with 1,2,4-triazole in the presence of phosphorus oxychloride, followed by reaction with hydroxylamine reagent, and finally acid deprotection to obtain the compound of formula I. The synthetic route is as follows:

[0006] This synthetic route involves five steps to prepare monavir. The starting material, uridine, is relatively expensive and has a low overall yield. Phosphorus oxychloride is used in the process, which is highly toxic and produces a large amount of acidic wastewater. Therefore, this process is not suitable for industrial production.

[0007] Route 2: Chemical Communications (2020), 56(87), 13363-13364 reported a two-step route for monabivir, including esterification and hydroximation of cytidine. The synthetic route is as follows:

[0008] The above-mentioned process uses enzyme-catalyzed reactions, which have high requirements on the catalyst loading, solvent and the quality of enzyme-catalyzed raw materials.

[0009] Route 3: Synlett (2021), 32(3), 326-328 discloses a synthetic route using cytidine as a raw material as follows:

[0010] The four-step reaction yield is 44%. This route has the advantage of using the relatively cheap cytidine as a raw material and avoiding the more difficult triazole reaction step. However, this process still has problems such as the instability of intermediate 3, low monoacylation efficiency, and difficulty in separating and purifying the product.

[0011] Given the widespread prevalence of COVID-19 around the world, providing an industrially feasible and economical raw material synthesis route is of great significance to the global fight against the epidemic.

[0012] Summary of the Invention

[0013] The purpose of the present invention is to provide a method for preparing monabivir which is suitable for industrial production and easy to separate and purify.

[0014] The first aspect of the present invention provides a method for synthesizing monabivir represented by formula I, comprising the following steps:

[0015] Step a: reacting the compound of formula III with acetone under acidic conditions to obtain the compound of formula IV,

[0016] Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain a compound of formula V,

[0017] Step c: reacting the compound of formula V with ammonia or hydroxylamine to obtain the compound of formula VI,

[0018] Step d: removing the protecting group of the compound of formula VI in a solvent under the action of an acid to obtain monabivir of formula I,

[0019] The second aspect of the present invention provides a method for synthesizing monabivir according to formula I, comprising the following steps:

[0020] Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain a compound of formula V;

[0021] Step c: reacting the compound of formula V with ammonia or hydroxylamine to obtain the compound of formula VI;

[0022] Step d: removing the protecting group of the compound of formula VI in a solvent under the action of an acid to obtain monabivir of formula I.

[0023] The third aspect of the present invention provides a method for synthesizing monabivir according to formula I, comprising the following steps:

[0024] Step c: reacting the compound of formula V with ammonia or hydroxylamine to obtain the compound of formula VI;

[0025] Step d: removing the protecting group of the compound of formula VI in a solvent under the action of hydrobromic acid to obtain monabivir of formula I.

[0026] The fourth aspect of the present invention provides a method for synthesizing monabivir according to formula I, comprising the following steps:

[0027] Step d: removing the protecting group of the compound of formula VI in a solvent under the action of hydrobromic acid to obtain monabivir of formula I.

[0028] A fifth aspect of the present invention provides a method for synthesizing a compound of formula VI, comprising the following steps:

[0029] Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain a compound of formula V;

[0030] Step c: reacting the compound of formula V with ammonia or hydroxylamine to obtain the compound of formula VI.

[0031] The process of obtaining intermediate VI from intermediate IV via intermediate V has the advantages of high double acylation directional conversion rate, high yields in both steps, and few side reactions.

[0032] A sixth aspect of the present invention provides a method for synthesizing a compound of formula V, comprising the following steps:

[0033] Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain a compound of formula V;

[0034] A seventh aspect of the present invention provides a method for synthesizing a compound of formula V, comprising the following steps:

[0035] Step a: reacting the compound of formula III with acetone under acidic conditions to obtain the compound of formula IV;

[0036] Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain the compound of formula V.

[0037] In an eighth aspect of the present invention, there is provided a method for preparing compound IV, comprising the following steps:

[0038] Step a: reacting the compound of formula III with acetone under acidic conditions to obtain the compound of formula IV.

[0039] The compound of Formula III can be obtained by reacting cytidine and hydroxylamine sulfate in a solvent. After the reaction, the reaction is filtered and centrifuged to obtain the compound of Formula III. The molar ratio of cytidine to hydroxylamine sulfate is 1:0.5-1.5. The solvent is selected from tetrahydrofuran, acetonitrile, water, or a mixture thereof.

[0040] The ninth aspect of the present invention provides a compound represented by formula V and its use as an intermediate for synthesizing monabivir.

[0041] According to a preferred embodiment of the present invention, the acid in step a is sulfuric acid, methanesulfonic acid or p-toluenesulfonic acid.

[0042] According to a preferred embodiment of the present invention, the molar ratio of the compound of formula III to the acid in step a is 1:1.0-3.0, preferably 1:1.5-2.5; the mass volume ratio of the compound of formula III to acetone is 1:4-100 g / ml, preferably 1:6-20 g / ml.

[0043] After the reaction in step a is completed, base is added to quench the reaction, and then post-treatment is performed to obtain the compound of formula IV.

[0044] According to a preferred embodiment of the present invention, the organic solvent in step b is one or more of dichloromethane, toluene, 2-methyltetrahydrofuran, and dioxane.

[0045] According to a preferred embodiment of the present invention, the base in step b is an organic base, preferably one or more of triethylamine and N,N,-diisopropylethylamine.

[0046] According to a preferred embodiment of the present invention, the step b reaction further comprises a catalyst, preferably 4-dimethylaminopyridine; the molar ratio of the catalyst to the compound of formula IV is preferably 0.1 to 1.0:1.

[0047] According to a preferred embodiment of the present invention, the molar ratio of the compound of formula IV described in step b to isobutyryl chloride or isobutyric anhydride is 1:2.0-3.0.

[0048] According to a preferred embodiment of the present invention, in step c, the molar ratio of the compound of formula V to ammonia water or hydroxylamine is 1:1-20.

[0049] According to a preferred embodiment of the present invention, the solvent in step d is selected from methanol, ethanol, isopropanol, acetone, butanone, tetrahydrofuran, acetonitrile, water or a mixture thereof; preferably acetonitrile.

[0050] According to a preferred embodiment of the present invention, the acid in step d is selected from hydrochloric acid, hydrobromic acid, perchloric acid, formic acid, acetic acid or a mixture thereof.

[0051] According to a preferred embodiment of the present invention, the acid in step d is preferably hydrobromic acid, under which conditions the hydrolysis by-products are less and the product is easier to separate, especially in an acetonitrile system.

[0052] According to a preferred embodiment of the present invention, the volume mass ratio of the solvent in step d to the compound of formula IV is 1 to 50:1 ml / g, preferably 6 to 15:1 ml / g; the molar ratio of the compound of formula VI in step d to the acid is 1:0.5 to 20, preferably 1:1 to 2.

[0053] Compared with the prior art, the monabivir provided by the present invention has cheap raw material sources, no enzyme catalysis reaction, mild reaction conditions, simple operation, stable quality, high total yield, and less three wastes, making it very suitable for industrial production. DETAILED DESCRIPTION

[0054] The following specific implementations are further detailed descriptions of this article.

[0055] Unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures used herein are all conventional procedures widely used in the relevant fields.

[0056] Terms and descriptions:

[0057] When describing the compounds, compositions, methods and processes of the present invention, the following terms have the following meanings unless otherwise indicated. In addition, unless the context of use clearly dictates otherwise, as used herein, the singular forms "a", "an" and "the" include the corresponding plural forms.

[0058] The terms “having,” “comprising,” and “including” should be interpreted as open-ended, indicating the presence of the listed elements but not excluding the existence, occurrence, or addition of any other element or elements that are not listed.

[0059] All ranges recited herein include those endpoints of the range between the two values ​​recited.All values ​​recited herein, whether stated or not, include the degree of expected experimental error, technical error, and instrumental error for the given technique used to measure the value.

[0060] Herein, % is weight / weight (w / w) percentage unless otherwise stated.

[0061] Unless otherwise indicated, any numerical value, such as a concentration or a range of concentrations recited herein, is to be understood as being modified in all instances by the term "about."

[0062] In this document, unless otherwise indicated, the term "about" is intended to qualify the numerical value it modifies, indicating that such value may vary within a certain range. When no range is stated (e.g., a margin of error or the standard deviation of the mean value given in a graph or data table), the term "about" should be understood to mean a larger range that includes the stated value, as well as a range that is rounded to the nearest integer, taking into account significant figures, and a range that includes plus or minus 10% of the stated value.

[0063] In the present invention, dimethyltetrahydrofuran and 2-methyltetrahydrofuran (2-MeTHF) have the same meaning.

[0064] In some embodiments of the present invention, the acid in step a is sulfuric acid, methanesulfonic acid or p-toluenesulfonic acid.

[0065] In some embodiments of the present invention, the molar ratio of the compound of formula III to the acid in step a is 1:1.0-3.0, preferably 1:1.5-2.5; the mass volume ratio of the compound of formula III to acetone is 1:4-100 g / ml, preferably 1:6-20 g / ml.

[0066] In some embodiments of the present invention, the acid used in step a is sulfuric acid, such as sulfuric acid with a mass percentage concentration of 70-98%. After dissolving the compound of formula III in a solvent, sulfuric acid is slowly added, for example, dropwise, with stirring.

[0067] After the reaction in step a is completed, alkali is added for quenching, and then post-processing is performed to obtain the compound of formula IV. In some embodiments of the present invention, post-processing can be concentration, extraction, and crystallization; or the product can be directly used in the next reaction after concentration.

[0068] In some embodiments of the present invention, the organic solvent in step b is one or more of dichloromethane, toluene, 2-methyltetrahydrofuran, and dioxane.

[0069] In some embodiments of the present invention, the base in step b is an organic base, preferably one or more of triethylamine and N,N,-diisopropylethylamine, and the molar ratio of the organic base to the compound of formula V can be 1 to 10:1, for example, 1 to 5:1.

[0070] In some embodiments of the present invention, the step b reaction further comprises a catalyst, and the catalyst is preferably 4-dimethylaminopyridine; the molar ratio of the catalyst to the compound of formula IV is preferably 0.1 to 1.0:1, for example 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.8:1, 1.0:1 or any value or range therebetween.

[0071] In some embodiments of the present invention, the molar ratio of the compound of formula IV described in step b to isobutyryl chloride or isobutyric anhydride is 1:2.0-3.0.

[0072] In some embodiments of the present invention, in step b, after adding the compound of formula IV to an organic solvent, a base and a catalyst are added, and isobutyryl chloride or isobutyric anhydride is added dropwise at -5 to 5°C, for example, -5 to 0°C. After the addition is complete, the reaction is carried out at 0 to 20°C.

[0073] In some embodiments of the present invention, in step b, after the reaction is completed, the filter is pressed, and the filtrate is washed with water and hydrochloric acid in sequence. After the system is separated into layers, the organic layer is collected and used directly in the next reaction or concentrated and purified for the next reaction.

[0074] In some embodiments of the present invention, in step b, after the reaction is completed, the system is concentrated, an organic solvent (such as dichloromethane) is added to dissolve the residue, the organic phase is washed with water and hydrochloric acid in sequence, the system is separated and the organic layer is collected, and the solution containing the compound of formula V is directly used in the next reaction or concentrated and purified for the next reaction. In some embodiments of the present invention, in step b, the organic solvent is dichloromethane, after the reaction is completed, the filter is pressed, and the filtrate is washed with water and hydrochloric acid in sequence, the system is separated and the organic layer is collected and used directly in the next reaction or concentrated and purified for the next reaction.

[0075] In some embodiments of the present invention, in step b, the organic solvent is dimethyltetrahydrofuran. After the reaction is completed, the system is concentrated, dichloromethane is added to dissolve the residue, and the organic phase is washed sequentially with water and hydrochloric acid. After the system is separated into layers, the organic layer is collected, and the solution containing the compound of formula V is directly used in the next reaction or concentrated and purified before use in the next reaction. The content of the compound of formula V in the solution containing the compound of formula V can be determined by an external standard method.

[0076] In step b, the solvent can be recycled.

[0077] According to a preferred embodiment of the present invention, in step c, the molar ratio of the compound of formula V to ammonia water or hydroxylamine is 1:1-20.

[0078] In some embodiments of the present invention, in step c, the reaction comprises the following steps:

[0079] The compound of formula V is dissolved in toluene, and aqueous ammonia is added for reaction. After the reaction is completed, the organic phase is concentrated and purified by crystallization. The aqueous ammonia used can be an aqueous solution of 10% to 30% ammonia, such as an aqueous solution of 10% to 20% (e.g., 10%, 15%, 17%, 19%), 20% to 25%, 25% to 30% or any value or range therebetween.

[0080] In some embodiments of the present invention, in step c, a hydroxylamine aqueous solution is added to a dichloromethane solution containing a solution of the compound of formula V for reaction. After completion of the reaction, the organic phase is separated, washed, concentrated, and then purified by crystallization. The hydroxylamine aqueous solution used can be an aqueous solution of 10% to 80% (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or any value and range therebetween) hydroxylamine.

[0081] In some embodiments of the present invention, in step c, the solvent for crystallization purification can be an alkane solvent, such as petroleum ether, n-hexane, n-heptane, etc.; an ether solvent, such as diethyl ether, methyl tert-butyl ether, etc.; an alcohol solvent, such as methanol, ethanol, isopropanol, etc., or a mixed solvent of the above solvents and water.

[0082] In some preferred embodiments of the present invention, in step c, the crystallization solvent is n-heptane.

[0083] In some preferred embodiments of the present invention, in step c, the crystallization solvent is methyl tert-butyl ether.

[0084] In some preferred embodiments of the present invention, in step c, the crystallization solvent is a mixed solvent of methanol and water, which helps to prevent electrostatic effects.

[0085] In some preferred embodiments of the present invention, in step c, the crystallization solvent is a 10-50% alcohol aqueous solution, such as 10%, 15%, 20%, 25%, 30%, 35% or any value and range therebetween of methanol aqueous solution.

[0086] In some embodiments of the present invention, the reactions in step b and step c are carried out using the same organic solvent (eg, dichloromethane), without the need to convert the solvent, and the reaction operation is simpler.

[0087] In some embodiments of the present invention, in step c, the isopropionyl ester on the hydroxyoxime group in V is directed to be removed with a base to obtain a compound of formula VI. The compound of formula VI is insoluble in water and can be directly used in the next reaction after a simple water washing to remove the alkaline substance.

[0088] In some embodiments of the present invention, the solvent in step d is selected from methanol, ethanol, isopropanol, acetone, butanone, tetrahydrofuran, acetonitrile, water or a mixture thereof; preferably acetonitrile.

[0089] In some embodiments of the present invention, the acid in step d is selected from one of hydrochloric acid, hydrobromic acid, perchloric acid, formic acid, acetic acid, or a mixture thereof, preferably hydrochloric acid or hydrobromic acid, and the molar ratio of the hydrochloric acid or hydrobromic acid to the compound of formula VI is 1:1 to 1:2, for example, 1:1, 1:1.5 or 1:2.

[0090] In some embodiments of the present invention, the acid in step d is preferably hydrobromic acid, under which conditions the hydrolysis by-products are less and the product is easier to separate, especially in an acetonitrile system.

[0091] In some embodiments of the present invention, the volume mass ratio of the solvent in step d to the compound of formula IV is 1-50:1 ml / g, preferably 6-15:1 ml / g; the molar ratio of the compound of formula VI in step d to the acid is 1:0.5-20, preferably 1:1-2.

[0092] The present invention is further described below by way of examples, which are intended for illustrative purposes only and are not intended to limit the scope of the present invention in any way.

[0093] Example 1: Synthesis of compound of formula III

[0094] 4.2 L of purified water, 2.1 kg of cytidine, and 708.6 g of hydroxylamine sulfate (0.5 eq) were added to the reaction kettle, and the temperature was raised to 70° C. to 80° C. and stirred for 10 to 20 hours. After the reaction was completed, the mixture was cooled, centrifuged, rinsed, and dried to obtain 1.8 kg of compound III with a yield of 75% and a purity of >98%.

[0095] Example 2: Synthesis of compound of formula III

[0096] Add 21 ml of tetrahydrofuran, 63 ml of water, 21 g of cytidine, and 21.8 g of hydroxylamine sulfate (1.5 eq) to the reaction flask, heat to 70° C. to 80° C., and stir for 10 to 20 h. After the reaction is completed, cool, centrifuge, rinse, and dry to obtain 19 g of the monohydrate of the compound of formula III with a yield of 79.4% and a purity of >98%.

[0097] Example 3: Synthesis of compound of formula IV

[0098] 100 g of the monohydrate of compound III was dissolved in 800 ml of acetone, and 81.4 g of concentrated sulfuric acid (2.3 eq) was added dropwise. After completion of the addition, the mixture was stirred for 3 h. After the reaction was complete, the system was cooled to 0°C and quenched by the addition of 190 g of triethylamine (5.2 eq). The mixture was concentrated, extracted with ethyl acetate / water, and crystallized to obtain 97 g of compound IV in an 89.8% yield and 98% purity. Mz: 300. 1H NMR (400MHz, DMSO) δ10.03(s,1H),9.59(s,1H),6.98(d,J=8.2Hz,1H),5.76(t,J=4.7Hz,1H),5.57(dd,J=8.1,1.5Hz,1H),5.06–4.97(m,1H),4.81(dd ,J=6.4,3.2Hz,1H),4.71(dd,J=6.4,3.7Hz,1H),4.00–3.94(m,1H),3.60–3 .48(m,2H),1.99(s,1H),1.91(s,1H),1.48(s,3H),1.27(d,J=10.2Hz,3H).

[0099] Example 4: Synthesis of compound of formula IV

[0100] 100 g of compound III was dissolved in 1000 ml of acetone, and 106 g of concentrated sulfuric acid (3 eq) was added dropwise. After the addition was complete, the mixture was stirred for 3 h. After the reaction was completed, the system was cooled to 0° C. and quenched by adding 220 g of triethylamine (6 eq). The mixture was concentrated to obtain 100 g of compound IV as an oil with an external standard yield of 90% and a purity of 90%.

[0101] Example 5: Synthesis of compound of formula V

[0102] 50 g of the compound of Formula IV was added to 700 ml of dichloromethane, 4.08 g of DMAP (0.2 eq), and 84.5 g of triethylamine (5.0 eq). The mixture was cooled to 0°C, and 53.4 g of isobutyryl chloride (3.0 eq) was added dropwise. The mixture was reacted at 20°C for 15 h, filtered, washed with 500 ml of water, and then washed with 1N hydrochloric acid. The layers were separated to obtain a dichloromethane solution of the compound of Formula V. The solution was concentrated and crystallized to obtain 69.7 g of the compound of Formula V, with a yield of 95% and a purity of 98%. MS-ESI (m / z): [M+H] + 440. 1 H NMR (400MHz, DMSO-d6) δ10.97(s,1H),7.28(dd,J=33.9,8.2Hz,1H),5.79–5.69(m,2H),5.01(dd,J=6.5,2.1Hz,1H),4.77(dt,J=9.4,4.7Hz,1 H),4.28–4.13(m,3H),2.89–2.64(m,1H),2.62–2.52(m,1H),1.99(s,1H),1.48(d,J=4.2Hz,3H),1.28(d,J=13.1Hz,3H),1.13–1.05(m,12H).

[0103] Example 6: Synthesis of compound of formula V

[0104] 50 g of the compound of formula IV was added to 500 ml of dimethyltetrahydrofuran, 20.4 g of DMAP (1.0 eq), and 108.06 g of N,N-diisopropylethylamine (5.0 eq). The mixture was cooled to 0° C., and 52.9 g of isobutyric anhydride (2.0 eq) was added dropwise. After the addition was complete, the mixture was reacted at 20° C. for 15 h, concentrated, and 500 ml of dichloromethane was added. The mixture was washed with 500 ml of water and 1N hydrochloric acid. The layers were separated to obtain a dichloromethane solution of the compound of formula V with a purity of 95%.

[0105] Example 7: Synthesis of compound of formula VI

[0106] 20 g of the compound of formula V was added to 100 ml of toluene, and 91 g of 17% aqueous ammonia (20.0 eq) was added. The temperature was raised to 30° C. and stirred for 15 h. After the reaction was completed, the layers were separated and washed twice with water. The toluene phase was concentrated, and n-heptane was added for crystallization. The mixture was filtered to obtain 15.1 g of the compound of formula VI as a white powder with a yield of 89.8% and a purity of 99%.

[0107] Example 8: Synthesis of compound of formula VI

[0108] To a dichloromethane solution containing 20 g of compound V was added 3 g of 50% aqueous hydroxylamine solution (1.0 eq), the temperature was raised to 30 ° C and stirred for 15 h. After the reaction was completed, the layers were separated and washed twice with water. The dichloromethane phase was concentrated, and n-heptane was added for crystallization. The product was filtered to obtain 14.3 g of compound VI as a white powder with a yield of 85% and a purity of 99%.

[0109] Example 9: Synthesis of Monabiravir

[0110] 15 g of the compound of formula VI was added to 105 ml of acetonitrile, the temperature was raised to 50° C., 8.21 g of HBr (1.0 eq) aqueous solution was added dropwise, and the mixture was stirred for 2 h. After the reaction was completed, the acetonitrile was removed by concentration, and water and ethyl acetate were added for extraction. The aqueous layer was extracted three times with ethyl acetate. The organic layers were combined, concentrated, crystallized, and dried to obtain 12 g of crude monabivir with a purity of >99% and a yield of 90%.

[0111] Example 10: Synthesis of Monabiravir

[0112] 15 g of the compound of formula VI was added to 150 ml of tetrahydrofuran, the temperature was raised to 50° C., 6.09 g of a 35% concentrated hydrochloric acid solution (1.5 eq) was added dropwise, and the mixture was stirred for 2 h. After the reaction was completed, the mixture was concentrated, and water and ethyl acetate were added for extraction. The aqueous layer was extracted three times with ethyl acetate. The organic layers were combined, concentrated, crystallized, and dried to obtain 9.4 g of monabivir with a purity of >98% and a yield of 70%.

[0113] Example 11: Synthesis of Monabiravir

[0114] 15 g of the compound of formula VI was added to 38.2 g of 98% formic acid (20 eq), and the mixture was stirred at 40° C. for 20 h. After the reaction was completed, the mixture was concentrated, and water and ethyl acetate were added for extraction. The aqueous layer was extracted three times with ethyl acetate. The organic layers were combined, concentrated, crystallized, and dried to obtain 10.7 g of monabivir with a purity of >98% and a yield of 80%.

[0115] Example 12: Recrystallization of Monabiravir

[0116] 12 g of the monabivir prepared in Example 9 was recrystallized once with 48 ml of water to obtain 10 g of monabivir finished product with a purity of 99.8% and a yield of 83.3%.

[0117] Example 13: Synthesis of compound of formula VI

[0118] To a dichloromethane solution containing 20 g of compound V was added 3 g of 50% aqueous hydroxylamine solution (1.0 eq), the temperature was raised to 30 ° C and stirred for 15 h. After the reaction was completed, the layers were separated and washed twice with water. The dichloromethane phase was concentrated and crystallized by adding 15% aqueous methanol. The product was filtered to obtain 14.3 g of compound VI as a white powder with a yield of 86% and a purity of 99%.

[0119] Example 14: Synthesis of compound of formula VI

[0120] 5 kg of the compound of formula IV was added to a reactor, and 70 L of dichloromethane, 0.408 kg of DMAP (0.2 eq), and 8.45 kg of triethylamine (5.0 eq) were added in sequence. The mixture was stirred and cooled to 0°C. 5.34 kg of isobutyryl chloride (3.0 eq) was added dropwise. After the addition was complete, the mixture was reacted at 20°C for 16 h. The mixture was filtered and the filtrate was poured into another reactor. The mixture was washed with 50 L of water and 15 L of 1N hydrochloric acid. The layers were separated to obtain a dichloromethane solution of the compound of formula V. 22.7 kg of aqueous ammonia (25% content, 20 eq) was added and the reaction was controlled at an internal temperature of 20-25°C for 8 h. The mixture was allowed to stand, separated, washed with water twice, and the dichloromethane phase was concentrated. 15% aqueous methanol was added for crystallization and filtered to obtain 5.55 kg of white powdered compound VI with a yield of 89.9% and a purity of 99%.

[0121] Comparative Example: Synthesis of Compounds of Formula I

[0122] Compounds of formula V are first subjected to acidic treatment to remove the propylidene protecting group and then to remove the isopropionyl ester on the hydroxyoxime group. This presents the following problems: when removing the propylidene protecting group, formic acid is used, which consumes a large amount of formic acid and results in incomplete conversion. Post-treatment requires the formic acid to be concentrated, followed by the addition of a base for deprotection. This operation is cumbersome, consumes a large amount of solvent, and the concentration process also poses quality risks. The use of other stronger acids, such as hydrochloric acid and trifluoroacetic acid, produces a large number of byproducts, such as isobutyl ester and hydrolysis products of the hydroxyoxime ester, which affect the yield and quality.

[0123] It should be noted that all documents and patents mentioned in this application are incorporated herein by reference, just as if each document or patent were individually incorporated by reference. Furthermore, it should be understood that the above description is only a specific embodiment and technical principle of the present invention. After reading the above disclosure, those skilled in the art may make various improvements and modifications to the present invention without departing from the scope of the present invention, and such equivalent forms also fall within the scope of the present invention.

Claims

1. A method for synthesizing monabivir represented by formula I, comprising the following steps ad, bd or cd: Step a: reacting the compound of formula III with acetone under acidic conditions to obtain the compound of formula IV, Step b: reacting the compound of formula IV with isobutyryl chloride or isobutyric anhydride in an organic solvent under alkaline conditions to obtain a compound of formula V, Step c: reacting the compound of formula V with ammonia or hydroxylamine to obtain the compound of formula VI, Step d: removing the protecting group of the compound of formula VI in a solvent under the action of an acid to obtain monabivir of formula I, 2. A method for synthesizing a compound of formula VI, comprising steps b and c as described in claim 1.

3. A method for synthesizing monabivir represented by formula I, comprising step d as described in claim 1, wherein the acid is hydrobromic acid.

4. A method for synthesizing a compound of formula IV, comprising step a as claimed in claim 1.

5. A method for synthesizing a compound of formula V, comprising step b or steps ab as claimed in claim 1.

6. The synthesis method according to any one of claims 1, 4 or 5, wherein In step a, the acid is sulfuric acid, methanesulfonic acid or p-toluenesulfonic acid.

7. The synthesis method according to any one of claims 1, 4 or 5, wherein In step a, the molar ratio of the compound of formula III to the acid is 1:1.0-3.0, preferably 1:1.5-2.5; the mass volume ratio of the compound of formula III to acetone is 1:4-100 g / ml, preferably 1:6-20 g / ml.

8. The synthesis method according to any one of claims 1, 2 or 5, wherein In step b, the organic solvent is one or more of dichloromethane, toluene, 2-methyltetrahydrofuran or dioxane.

9. The method according to any one of claims 1, 2 or 5, wherein: In step b, the base is an organic base, preferably one or more of triethylamine or N,N,-diisopropylethylamine.

10. The synthesis method according to any one of claims 1, 2 or 5, wherein In step b, a catalyst is further included, and the catalyst is preferably 4-dimethylaminopyridine.

11. The synthesis method according to claim 10, wherein The molar ratio of the catalyst to the compound of formula IV is 0.1-1.0:

1.

12. The synthesis method according to any one of claims 1, 2 or 5, wherein The molar ratio of the compound of formula IV to isobutyryl chloride or isobutyric anhydride is 1:2.0-3.

0.

13. The synthesis method according to claim 1 or 2, wherein In step c, the molar ratio of the compound of formula V to ammonia or hydroxylamine is 1:1-20.

14. The synthesis method according to claim 1 or 3, wherein In step d, the solvent is selected from one or more of methanol, ethanol, isopropanol, acetone, butanone, tetrahydrofuran, acetonitrile, and water; 15. The synthesis method according to claim 1, wherein In step d, the acid is selected from one or more of hydrochloric acid, hydrobromic acid, perchloric acid, formic acid, and acetic acid.

16. The synthesis method according to claim 1 or 3, wherein In step d, the volume mass ratio of the solvent to the compound of formula IV is 1-50:1 ml / g, preferably 6-15:1 ml / g; the molar ratio of the compound of formula VI to the acid in step d is 1:0.5-20, preferably 1:1-2.